JP3827713B2 - 凝固因子viiiからなる医薬製剤 - Google Patents
凝固因子viiiからなる医薬製剤 Download PDFInfo
- Publication number
- JP3827713B2 JP3827713B2 JP50398795A JP50398795A JP3827713B2 JP 3827713 B2 JP3827713 B2 JP 3827713B2 JP 50398795 A JP50398795 A JP 50398795A JP 50398795 A JP50398795 A JP 50398795A JP 3827713 B2 JP3827713 B2 JP 3827713B2
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- viiisq
- subcutaneous
- viii
- coagulation factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9302308A SE504074C2 (sv) | 1993-07-05 | 1993-07-05 | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
SE9302308-3 | 1993-07-05 | ||
PCT/SE1994/000297 WO1995001804A1 (en) | 1993-07-05 | 1994-03-31 | A coagulation factor viii formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500624A JPH09500624A (ja) | 1997-01-21 |
JP3827713B2 true JP3827713B2 (ja) | 2006-09-27 |
Family
ID=20390516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50398795A Expired - Fee Related JP3827713B2 (ja) | 1993-07-05 | 1994-03-31 | 凝固因子viiiからなる医薬製剤 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5972885A (de) |
EP (1) | EP0710114B2 (de) |
JP (1) | JP3827713B2 (de) |
AT (1) | ATE233099T1 (de) |
AU (1) | AU6762794A (de) |
CA (1) | CA2163112C (de) |
DE (1) | DE69432179T3 (de) |
DK (1) | DK0710114T4 (de) |
ES (1) | ES2193159T5 (de) |
MX (1) | MX9402339A (de) |
PT (1) | PT710114E (de) |
SE (2) | SE504074C2 (de) |
WO (1) | WO1995001804A1 (de) |
ZA (1) | ZA942035B (de) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US7253262B2 (en) | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
SE9502285D0 (sv) * | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Improvements related to injections |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7560107B2 (en) * | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
US20030143662A1 (en) | 1998-06-16 | 2003-07-31 | Cummings Richard D. | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof |
MXPA00012586A (es) * | 1998-06-16 | 2004-05-21 | Univ Oklahoma | Glicosulfopeptidos y metodos de sintesis y uso de los mismos. |
RU2244556C2 (ru) | 1999-02-22 | 2005-01-20 | Юниверсити Оф Коннектикут | Новые не содержащие альбумин составы фактора viii |
GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
CA2788505C (en) * | 2003-02-26 | 2018-09-04 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
CA2465004A1 (en) * | 2003-05-19 | 2004-11-19 | National Institute For Biological Standards And Control | Composition |
CN1266144C (zh) * | 2003-09-01 | 2006-07-26 | 上海凯曼生物科技有限公司 | 黄芩甙和黄芩甙元的用途和剂型 |
ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
DE102004005095A1 (de) | 2004-01-27 | 2005-09-22 | Coty B.V. | Kosmetische Zusammensetzung mit wasserbeständiger Parfümkomponente |
EP1750733B1 (de) * | 2004-05-03 | 2013-12-11 | Emory University | Verfahren zur verabreichung von schweine b-domänenlosem fviii |
SI3130601T1 (sl) * | 2004-11-12 | 2020-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
TWI264608B (en) * | 2005-04-08 | 2006-10-21 | Delta Electronics Inc | Light tunnel module |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
CA2690218C (en) | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
JP5779780B2 (ja) | 2008-11-07 | 2015-09-16 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 第viii因子製剤 |
CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
PL3266463T3 (pl) | 2009-06-09 | 2024-03-18 | Prolong Pharmaceuticals, LLC | Kompozycje hemoglobiny |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
ES2856055T3 (es) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre |
ES2590679T3 (es) | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2769326A1 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
KR20120061898A (ko) * | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
CA2782424C (en) | 2009-12-06 | 2021-07-27 | Biogen Idec Hemophilia Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
US20130216513A1 (en) | 2010-07-09 | 2013-08-22 | Biogen Idec Hemophilia Inc. | Chimeric Clotting Factors |
CN104788557A (zh) * | 2010-09-15 | 2015-07-22 | 诺沃—诺迪斯克有限公司 | 具有减少的细胞摄取的因子viii变体 |
SG10201509149VA (en) | 2010-11-05 | 2015-12-30 | Baxter Int | A new variant of antihemophilic factor viii having increased specific activity |
KR102025442B1 (ko) | 2010-12-22 | 2019-09-25 | 박스알타 인코퍼레이티드 | 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법 |
EP2709648A4 (de) | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | Verbindungen zur bindung an den erythropoietinrezeptor |
HUE039317T2 (hu) * | 2011-06-10 | 2018-12-28 | Baxalta GmbH | Koagulációs betegség kezelése rekombináns VWF adagolásával |
US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
WO2013009627A2 (en) | 2011-07-08 | 2013-01-17 | Biogen Idec Hemophilia Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
US10656167B2 (en) | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
AU2012318303B2 (en) | 2011-10-18 | 2015-09-03 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII |
KR20140083036A (ko) | 2011-10-18 | 2014-07-03 | 체에스엘 베링 게엠베하 | 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도 |
PT2804623T (pt) | 2012-01-12 | 2019-11-18 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos do fator viii e suas utilizações |
ES2899848T3 (es) | 2012-01-12 | 2022-03-15 | Bioverativ Therapeutics Inc | Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII |
LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | キメラ性凝固因子 |
EP4079316A1 (de) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Prokoagulatorische verbindungen |
EP3404105A1 (de) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon |
BR112015000267B1 (pt) | 2012-07-11 | 2023-01-24 | Bioverativ Therapeutics Inc. | Proteínas quiméricas, e composição farmacêutica |
EP2877202A4 (de) | 2012-07-25 | 2016-06-01 | Biogen Ma Inc | Blutfaktorüberwachungstest und verwendungen davon |
EP2908847B1 (de) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors |
EP3943102A1 (de) | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Verfahren zur verwendung von fviii-polypeptid |
FI2956477T4 (fi) | 2013-02-15 | 2024-04-24 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
UY35462A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulación de un polipéptido del factor viii. |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
EP2989123A4 (de) * | 2013-04-22 | 2016-10-12 | Scripps Research Inst | Verfahren und zusammensetzungen zur behandlung von blutungsstörungen |
EP2796145B1 (de) | 2013-04-22 | 2017-11-01 | CSL Ltd. | Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke |
NZ713904A (en) | 2013-06-28 | 2022-02-25 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
EP3875106A1 (de) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Reinigung von chimären fviii-molekülen |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
EP3065769A4 (de) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Prokoagulatorische fusionsverbindung |
WO2015085276A1 (en) | 2013-12-06 | 2015-06-11 | Biogen Idec Ma Inc. | Population pharmacokinetics tools and uses thereof |
CN116621991A (zh) | 2014-01-10 | 2023-08-22 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
EP3102589A1 (de) | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen |
CN106414492B (zh) | 2014-06-06 | 2021-07-06 | 奥克塔法马股份有限公司 | 包含因子viii和冯·维勒布兰德因子肽的制剂 |
US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
CN108884145B (zh) | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
JP6695426B2 (ja) | 2015-11-13 | 2020-05-20 | バクスアルタ インコーポレイテッド | 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター |
PL3411478T3 (pl) | 2016-02-01 | 2022-10-03 | Bioverativ Therapeutics Inc. | Geny zoptymalizowanego czynnika VIII |
WO2017222337A1 (ko) | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 |
JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
EP3548066A1 (de) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Verfahren zur behandlung von hämophile arthropathie unter verwendung chimärer gerinnungsfaktoren |
MX2019006446A (es) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Métodos para inducir tolerancia inmunológica a factores de coagulación. |
SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
US11446365B2 (en) | 2017-08-09 | 2022-09-20 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
IL277713B2 (en) | 2018-04-04 | 2024-09-01 | Sigilon Therapeutics Inc | Implantable particles and related methods |
SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
TW202006141A (zh) | 2018-07-16 | 2020-02-01 | 美商巴克斯歐塔公司 | 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法 |
BR112021002017A2 (pt) | 2018-08-09 | 2021-05-11 | Bioverativ Therapeutics Inc. | moléculas de ácido nucleico e usos das mesmas para terapia genética não viral |
UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
EA202191977A1 (ru) | 2019-01-16 | 2021-12-15 | Баксалта Инкорпорейтед | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии а |
BR112021025426A2 (pt) | 2019-06-19 | 2022-06-21 | Bioverativ Therapeutics Inc | Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea |
US20230023826A1 (en) | 2019-12-12 | 2023-01-26 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
WO2021165226A1 (en) | 2020-02-17 | 2021-08-26 | Biotest Ag | Subcutaneous administration of factor viii |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
EP4355768A1 (de) | 2021-06-14 | 2024-04-24 | Takeda Pharmaceutical Company Limited | Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression |
WO2023028456A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
WO2023056331A1 (en) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4027013A (en) * | 1976-01-22 | 1977-05-31 | William L. Wilson | Clottable fibrinogen free factor VIII and albumin product and process |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US4495175A (en) * | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
IL74909A (en) * | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
ES8801674A1 (es) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
NO872932L (no) * | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. |
US5171844A (en) * | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5204323B1 (en) * | 1988-10-06 | 1995-07-18 | Ciba Geigy Corp | Hirudin antidotal compositions and methods |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
SE468050C (sv) * | 1991-03-15 | 1998-04-27 | Pharmacia & Upjohn Ab | Rekombinant derivat av human faktor VIII |
DE4111393A1 (de) † | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
GB9122609D0 (en) † | 1991-10-24 | 1991-12-04 | Brownlee George G | Improvements relating to the treatment of haemophilia |
GB9211538D0 (en) * | 1992-06-01 | 1992-07-15 | Blake David R | Antiinflammatory agent |
ATE198277T1 (de) † | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
US5563045A (en) * | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
AU5602394A (en) * | 1992-11-13 | 1994-06-08 | Duke University | Chimeric blood coagulation proteins |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
-
1993
- 1993-07-05 SE SE9302308A patent/SE504074C2/sv not_active IP Right Cessation
-
1994
- 1994-03-23 ZA ZA942035A patent/ZA942035B/xx unknown
- 1994-03-30 MX MX9402339A patent/MX9402339A/es active IP Right Grant
- 1994-03-31 JP JP50398795A patent/JP3827713B2/ja not_active Expired - Fee Related
- 1994-03-31 SE SE9401105A patent/SE9401105D0/ unknown
- 1994-03-31 AU AU67627/94A patent/AU6762794A/en not_active Abandoned
- 1994-03-31 WO PCT/SE1994/000297 patent/WO1995001804A1/en active IP Right Grant
- 1994-03-31 AT AT94915722T patent/ATE233099T1/de active
- 1994-03-31 DK DK94915722.6T patent/DK0710114T4/da active
- 1994-03-31 US US08/564,161 patent/US5972885A/en not_active Expired - Lifetime
- 1994-03-31 PT PT94915722T patent/PT710114E/pt unknown
- 1994-03-31 EP EP94915722A patent/EP0710114B2/de not_active Expired - Lifetime
- 1994-03-31 ES ES94915722T patent/ES2193159T5/es not_active Expired - Lifetime
- 1994-03-31 CA CA002163112A patent/CA2163112C/en not_active Expired - Fee Related
- 1994-03-31 DE DE69432179T patent/DE69432179T3/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
SE504074C2 (sv) | 1996-11-04 |
ES2193159T5 (es) | 2011-07-29 |
DE69432179T2 (de) | 2003-07-24 |
SE9302308L (sv) | 1995-01-06 |
EP0710114A1 (de) | 1996-05-08 |
CA2163112A1 (en) | 1995-01-19 |
SE9302308D0 (sv) | 1993-07-05 |
DE69432179D1 (de) | 2003-04-03 |
MX9402339A (es) | 1995-01-31 |
WO1995001804A1 (en) | 1995-01-19 |
ATE233099T1 (de) | 2003-03-15 |
DK0710114T3 (da) | 2003-06-23 |
AU6762794A (en) | 1995-02-06 |
PT710114E (pt) | 2003-06-30 |
EP0710114B2 (de) | 2011-03-16 |
EP0710114B1 (de) | 2003-02-26 |
JPH09500624A (ja) | 1997-01-21 |
ES2193159T3 (es) | 2003-11-01 |
DE69432179T3 (de) | 2012-01-19 |
CA2163112C (en) | 2007-08-07 |
SE9401105D0 (sv) | 1994-03-31 |
ZA942035B (en) | 1995-01-05 |
US5972885A (en) | 1999-10-26 |
DK0710114T4 (da) | 2011-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3827713B2 (ja) | 凝固因子viiiからなる医薬製剤 | |
JP3939750B2 (ja) | 凝固第viii因子の皮下、筋肉内または皮内投与用の製薬調合剤 | |
JP3777467B2 (ja) | 安定化第viii因子調製物 | |
EP0700299B1 (de) | Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung | |
EP1016673B1 (de) | Zusammensetzung, welche den Koagulationsfaktor VIII beinhalted; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator | |
AU2012326080A1 (en) | Etanercept formulations stabilized with meglumine | |
JP3822383B2 (ja) | 可溶性トロンボモジュリン含有組成物 | |
KR100373882B1 (ko) | 인자ⅷ의피하,근내또는피내투여용약제학적제형 | |
JP2024528312A (ja) | ヒト血漿由来第viii因子/フォンヴィレブラント因子の製造方法および得られた組成物 | |
MXPA96004455A (en) | Pharmaceutical formulation for administracionsubcutanea, intramuscular or intradermica of factorviii or factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050421 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060501 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060705 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100714 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100714 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110714 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120714 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130714 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |